Literature DB >> 31454538

N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.

Hong Wang1, Bei Xu2, Jun Shi3.   

Abstract

N6-methyladenosine (m6A) is the most prevalent internal modification in mammalian mRNAs and methyltransferase-like 3 (METTL3) is a vital methyltransferase in m6A modification. Here, this study tries to discover the regulatory role of METTL3 and its mechanism in the breast cancer tumorigenesis. Results found that METTL3 was up-regulated in the breast cancer tissue and cells. In vivo and vitro, METTL3 knockdown could decrease the methylation level, reduce the proliferation, accelerate the apoptosis and inhibited the tumor growth. Moreover, we found that Bcl-2 acted as the target of METTL3, thereby regulating the proliferation and apoptosis of breast cancer. This study could reveal the potential mechanism of m6A modification in the breast cancer tumorigenesis, providing potential drug targets in the treatment.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bcl-2; Breast cancer; METTL3; N6-methyladenosine; m6A

Mesh:

Substances:

Year:  2019        PMID: 31454538     DOI: 10.1016/j.gene.2019.144076

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  64 in total

1.  Alternative splicing of METTL3 explains apparently METTL3-independent m6A modifications in mRNA.

Authors:  Hui Xian Poh; Aashiq H Mirza; Brian F Pickering; Samie R Jaffrey
Journal:  PLoS Biol       Date:  2022-07-19       Impact factor: 9.593

Review 2.  The Key Role of RNA Modification in Breast Cancer.

Authors:  Yang Liu; Tong Zhu; Yi Jiang; Jiawen Bu; Xudong Zhu; Xi Gu
Journal:  Front Cell Dev Biol       Date:  2022-06-01

3.  Adenylate Kinase 4 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an m6A-Based Epitranscriptomic Mechanism.

Authors:  Xiaochuan Liu; Gwendolyn Gonzalez; Xiaoxia Dai; Weili Miao; Jun Yuan; Ming Huang; David Bade; Lin Li; Yuxiang Sun; Yinsheng Wang
Journal:  Mol Ther       Date:  2020-09-05       Impact factor: 11.454

Review 4.  m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer.

Authors:  Huilin Huang; Hengyou Weng; Jianjun Chen
Journal:  Cancer Cell       Date:  2020-03-16       Impact factor: 31.743

Review 5.  Role of m6A in osteoporosis, arthritis and osteosarcoma (Review).

Authors:  Yibo Hu; Xiaohui Zhao
Journal:  Exp Ther Med       Date:  2021-06-30       Impact factor: 2.447

Review 6.  A mark of disease: how mRNA modifications shape genetic and acquired pathologies.

Authors:  Eliana Destefanis; Gülben Avşar; Paula Groza; Antonia Romitelli; Serena Torrini; Pınar Pir; Silvestro G Conticello; Francesca Aguilo; Erik Dassi
Journal:  RNA       Date:  2020-12-29       Impact factor: 4.942

7.  Upregulation of circular and linear METTL3 and USP3 in colorectal cancer.

Authors:  Bilal Alkhizzi; Mohammad Imran Khan; Ayat Al-Ghafari; Hani Choudhry
Journal:  Oncol Lett       Date:  2021-07-19       Impact factor: 3.111

8.  Effects of Quercetin on the Efficacy of Various Chemotherapeutic Drugs in Cervical Cancer Cells.

Authors:  Wenbin Xu; Shangdan Xie; Xin Chen; Shuya Pan; Hongfei Qian; Xueqiong Zhu
Journal:  Drug Des Devel Ther       Date:  2021-02-15       Impact factor: 4.162

Review 9.  The emerging role of RNA N6-methyladenosine methylation in breast cancer.

Authors:  Fangchao Zheng; Feng Du; Jiuda Zhao; Xue Wang; Yiran Si; Peng Jin; Haili Qian; Binghe Xu; Peng Yuan
Journal:  Biomark Res       Date:  2021-05-27

10.  METTL3‑mediated m6A modification of Bcl‑2 mRNA promotes non‑small cell lung cancer progression.

Authors:  Yongxi Zhang; Shuyuan Liu; Tiesuo Zhao; Chengxue Dang
Journal:  Oncol Rep       Date:  2021-06-16       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.